Centers specializing in coronary function testing are critical to ensure a systematic approach to the diagnosis and treatment of angina with nonobstructive coronary arteries (ANOCA). Management leveraging lifestyle, pharmacology, and device-based therapeutic options for ANOCA can improve angina burden and quality of life in affected patients. Multidisciplinary care teams that can tailor and titrate therapies based on individual patient needs are critical to the success of comprehensive programs. As coronary function testing for ANOCA is more widely adopted, collaborative research initiatives will be fundamental to improve ANOCA care. These efforts will require standardized symptom assessments and data collection, which will propel future large-scale clinical trials.
Competing Interests: Funding Support and Author Disclosures Dr Smilowitz has served on an advisory board for Abbott Vascular and is supported, in part, by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number K23HL150315. Dr Prasad has served on an advisory board and/or as a consultant for Abbott Vascular, Boston Scientific, Cardinol, CONAVI, Chiesi, and Neovasc. Dr Widmer has served on advisory boards for Abbott Vascular, Philips, and Medtronic; and has received research support from Cardiol Therapeutics. Dr Quesada is supported, in part, by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number K23HL151867. Dr Sutton has received honoraria for speaking or consulting from Abbott, Philips, Zoll, and Shockwave. Dr Lerman has served on an advisory board for Philips/Volcano. Dr Reynolds has received research support from Abbott Vascular, Philips, and Siemens. Dr Kesarwani has a consulting agreement with Abbott Vascular. Dr Sweeny has received honoraria from Abbott Vascular. Dr Park has received honoraria from Abbott Vascular and CSI. Dr Blair has received research support from Abbott Vascular and Philips; and is on a Speakers Bureau for Abbott Vascular. Dr Jeremias has consulting agreements with Philips, Abbott Vascular, ACIST, Neovasc, and CathWorks. Dr Kearney has consulting agreements with Abbott Vascular, Abiomed, Boston Scientific, CSI, Medtronic, Teleflex, and Philips. Dr Kobayashi has a consulting agreement with Abbott Vascular. Dr Miner has received investigator-initiated research support from Abbott Vascular. Dr Samuels has served as a consultant and has served on a Speaker’s Bureau for Abbott Vascular and Philips. Dr Shah has received research support from Abbott Vascular and the FDA of the U.S. Department of Health and Human Services (HHS). Dr Wei has served on an advisory board for Abbott Vascular. Dr Fearon has received institutional research support from Abbott Vascular, Medtronic, and the NIH (5R33HL139929-05); has a consulting agreement with CathWorks and Siemens; and has stock options with HeartFlow. Dr Henry has received research support and honoraria from Neovasc. Dr Moses has served as a consultant for Covanos; and has equity in Orchestra BioMed and Covanos. Dr Tremmel has received honoraria from and served on advisory boards for Abbott Vascular; has received honoraria and research funding from Boston Scientific; and has received honoraria from Shockwave. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(Copyright © 2023. Published by Elsevier Inc.)